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Abstract
The target of all adjuvant systemic therapies after surgery in breast
cancer is the eradication of a minimal subclinical residual disease.
Although it is well known that tumor cell dissemination takes place
already at an early stage of the disease, little is known about the
tumorbiological parameters of these residual cells. Selection of
patients eligible for adjuvant endocrine therapies is based on the
analysis of receptor expression in the primary tumor – although the
analysis is directed against disseminated tumor cells, these cells may
vary in receptor expression in comparison with the primary tumor.
In the current issue of Breast Cancer Research, Fehm and
colleagues present an analysis of estrogen receptor expres-
sion indicating considerable molecular differences between
the primary tumor and the corresponding disseminated tumor
cells (DTC) [1].
More than 20 years ago Bernhard Fisher raised the hypothe-
sis that breast cancer is a systemic disease even at an early
stage, rather than just locally restricted [2]. This opened the
gate to a dramatic change in therapeutic strategies, from
radical surgery to new concepts based on less radical local
therapy combined with additional therapeutic options such
as radiotherapy, endocrine treatment and cytotoxic
treatment. These modern multimodal strategies considerably
improved the outcome of breast cancer patients over the
past decades and proved – due to the success of this
approach – the hypothesis of breast cancer as a primarily
systemic disease [3].
The majority of early breast cancer patients to date receive a
combination of surgery, radiotherapy, endocrine treatment,
cytotoxic treatment or immunologic treatment. But do all
patients treated by these often highly toxic and side-effect-
causing regimens really need and benefit from these
treatments? We know that only a minority of approximately
10% to 20% of patients do really benefit from systemic
therapy [4]. We still do not, however, have suitable para-
meters predicting response to therapy or, more importantly,
the need for systemic therapy. Since some patients will have
long-term benefit from these strategies, the massive
overtreatment of the majority of breast cancer patients is
currently well accepted in the scientific community.
Since the 1980s DTC have been described in the bone
marrow of early breast cancer patients as well as in patients
with various other tumors [5,6]. The presence of these cells
seemed to prove the concept of a metastatic spread of tumor
cells already at a very early stage. The follow-up data of these
patients published over recent years, however, have clearly
indicated that the presence of these cells alone does not
necessarily reflect an active metastatic disease in every single
patient [7,8]. Although DTC are detectable in up to 40% of
early breast cancer patients, the majority remains disease-
free even over 10 years and longer. DTC therefore apparently
indicate a high-risk situation but not always an ongoing
metastatic tumor cell spread. Nevertheless, the detection of
DTC in bone marrow and blood has become one of the most
promising parameters for identifying high-risk breast cancer
patients – and may, moreover, allow monitoring of patients
under therapy in order to determine the therapy response in
the future.
Analysis of molecular parameters such as the expression of
Her2 receptors, estrogen receptors or progestin receptors
became routine clinical practice in breast cancer. These
parameters allow selection of patients eligible for specific
therapeutic strategies targeting receptor-expressing cells. For
example, treatment of breast cancer with tamoxifen is one of
the oldest strategies for targeted therapy in estrogen
receptor-positive patients. These parameters, however, are
routinely analyzed in the primary tumor itself. The receptor
expression between primary tumor and metastatic tissue may
vary [9]. The considerable number of therapy failures may be
explained by these molecular differences between cells of the
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primary tumor – surgically removed and histopathologically
analyzed – and the remaining DTC, which may later cause
tumor recurrence. If one may accept the concept that tumor
cell dissemination takes place already in small tumors and
DTC may eventually be detectable in various organs such as
bone marrow, it appears consequent to obtain molecular
details from those tumor cells that remain behind after surgery
– the so-called minimal residual disease. These cells would be
the real targets for any systemic therapy in order to prevent
them forming a clinically relevant metastatic disease.
Analyzing a large cohort of patients, Fehm and colleagues
demonstrated surprisingly dramatic differences in estrogen
receptor expression between the primary tumor and the
corresponding DTC. Of 107 patients with DTC in the bone
marrow, only in 30 cases could identical results for estrogen
receptor expression be obtained between the primary tumor
and the corresponding DTC [1]. These data became even
more complex taking into consideration the heterogeneity of
estrogen receptor expression between different DTC of the
same patient.
The results of Fehm and colleagues on the estrogen receptor
status of DTC force us to rethink our understanding of
treatment success and failure based on the old-fashioned
parameters obtained from a primary tumor as the predictor for
therapy response – a tumor that already is surgically removed
at the time we even start thinking of adjuvant therapeutic
options for a particular patient. Fehm and colleagues’ data
may ultimately suggest new and more appropriate parameters
to consider systemic therapies in breast cancer – obtainable
at various time points in various clinical situations, leading to
more individualized treatment options. Nevertheless, any new
strategy based on the characterization of DTC will have to be
proven by the strongest outcome parameter known in
oncology – the improvement of survival.
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